Caris & Co Initiates Coverage on C. R. Bard (BCR) with an Above Average
More News related to BCR
- 8th Circuit Denies C.R. Bard, Inc.'s 23(f) Petition in Urological Catheters Antitrust Case -- BCR
- Citi Downgrades C.R. Bard (BCR) to Hold
- David Moenning’s Daily State of the Markets: 11/03
- Bard Receives FDA Approval for the Flair(TM) Endovascular Stent Graft
- David Moenning's Daily State of the Markets: 10/23
More News related to New Coverage
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Caris & Co initiates coverage on C. R. Bard (NYSE: BCR) with an Above Average rating. Price target $106.
C. R. Bard, Inc. (Bard) is engaged in the designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Related Categories
New CoverageStocks Mentioned
+3.52Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
